Public reporting burden for this collection of infoonation is esttmated to average 1 hour per response, including the time for reViewing instructtons, searching eXisting data sources, gathering and maintaining the data needed, and co~eting and reviewing this collectton of information. Send comments regarding this burden estimate or any other aspect of this collection of infoonation, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suije 1204, Allington, VA 22202-4302. Respondents should be aware that notwithstanding any other proVision of law, no person shall be subject to any penalty for failing to comply \Vith a collection of information if ij does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
INTRODUCTION
Breast cancer (BC) is a molecularly heterogeneous disease, which can be categorized into subtypes based on the tumor biology. 1,2 HER2 over-expressing cancers (HER2+) for example, account for 25-30% of diagnosed BCs and are associated with early metastasis and poor survival prognosis. 3 Treatments for HER2+ BCs, such as trastuzumab (Herceptin), 4 directly target the HER2 cell membrane receptor. 5 Such treatments are specific to HER2+ BCs, with no effect on other tumor subtypes e.g. estrogen receptor overexpressing cancers (ER+, luminal A subtype). Similarly, ER+ BC are treated with endocrine therapies targeting either ER directly e.g. tamoxifen, 6 or production of the receptor ligand (estradiol) e.g. aromatase inhibitors. 7, 8 It is therefore crucial to molecularly profile a cancer to prescribe the correct program of treatment. Diagnosis and subsequent treatment of BC is often based on analysis of a single biopsy of a primary tumor, and the surrounding lymph nodes. However, this method is flawed in advanced stage cancers, as the molecular profile of the cancer may differ at metastatic sites and/or between metastases in different organs. 9 Furthermore, most advanced stage breast cancers that initially respond to targeted therapy, whether HER2+ or ER+, become resistant to treatment, generally in less than 12 months, resulting in disease progression. 10, 11 The molecular heterogeneity of BC tumors, coupled with the diverse mechanisms and dynamic nature of therapy resistance, [12] [13] [14] [15] [16] [17] [18] illustrate that this method of diagnosis is insufficient to predict a tumor's response to treatment. This accounts for the mixed clinical responses to treatment observed in advanced stage BC patients, where some sites regress while others see progression. Developing effective treatment strategies for BC requires the ability to identify the molecular subtypes of each tumor site, and understand the mechanisms involved in the development of therapeutic resistance. However, obtaining biopsies from each site multiple times over the course of treatment is not practical. We proposed that near-infrared emissive polymersomes (NIREPs), a brightly emissive nanostructure, can be targeted to signature cell surface proteins to enable quantitative, non-invasive optical imaging of molecularly heterogeneous sites of BC in vivo. In this DoD 2014-2015 annual report, we provide an update on our progress to develop antibody-conjugated NIREPs capable of distinguishing between phenotypically distinct BC cells.
Therien Group: In our prior work, we demonstrated that NIREPs featuring surfaces functionalized with the humanized anti-HER2 monoclonal antibody trastuznmab, were able to discliminate between HER2+ and HER2-cellli:nes in in vitro experiments (Figure 1d ). The intent of this project is to extend these studies by developing a series of other antibody-conjugated NIREPs, each targeting a specific breast cancer-relevant cell smface antigen. Each 1mique NIREP would contain a porphyrin oligomer fluorophore to enable wavelength-based detection of cell receptor type (Figme la-c). In a separate DOD proj ect (PI: .AmlStrong) it was found that NIREPs bearing antibodies targeted to EPCAM saw batch-to-batch variability in flow cytometly experiments for binding to EPCAM overexpressing cells. Investigation of new batches of anti-HER2-NIREPs found similar difficulties in reproducibility ( Figure 2 ). In some batches, high uptake of up to 85,000 NIREPs per HER2+ SKBR3 cell were observed; in others, uptake levels matched that of control NIREPs conjugated to an isotype-matched IgG antibody. This prompted us to reinvestigate our protocols in detail. Our previously used bicinchoninic assay (BCA) used to determine the degree of antibody functionalization on the surface on the NIREP was unable to distinguish between covalently bound-antibody and surface associated antibody. Therefore, the use of this assay to detemline the efficiency of different antibody-coupling chemistries in some cases may have yielded inaccurate data. We have therefore invested time optimizing our coupling protocols and characterization methods as described below.
Antibody Conjugation Strategies
We have developed fluoronitrobenzoic acid (FNB)-based chemistiy for the chemical conjugation of bioligands to the surface of NIREPs. The FNB group can be introduced onto the hydroxyl-temlinus of a polymer in a single, high yielding step, 19 and unlike maleimide chemish"ies, is stable to hydrolysis at mild pHs (Scheme 1). FNB is reactive to prinmy amines, which in the case of protein-based ligands, is readily available via the N-temlinus or surface lysine residues. The abundance of these residues in proteins such as antibodies 7 (Abs) means prior chemical modification of Abs is unnecessary. The Therien group has previously used FNB-based chemistry to successfully functionalize NIREPs with the cell-penetrating Tat peptide for tracking dendritic cells (DCs) in vivo. 20 In this work, conjugation of Tat to the FNB-functionalized polymer was carried out prior to polymersome formation, allowing the conjugation to be carried out in organic solvents; progress of the reaction could be monitored by UV-vis absorption as the resulting orthonitroaniline chromophore absorbs at 428 nm (Scheme 1). 19 Presence of the peptide did not adversely affect the resulting polymersome morphology.
HO~
We have adapted this FNB-based chemistry for the conjugation of whole antibodies to the surface of polymersomes with these considerations: Conjugation to FNB must 1) be carried out under mild, aqueous conditions in order in order to preserve antibody functionality; 2) occur post-polymersome formation, as the large, hydrophilic nature of antibodies would likely disrupt the polymer's ability to form stable vesicle structures due to a vastly altered hydrophobic fraction. 21 It has already been demonstrated that polymersomes, once formed, are stable to surface decoration with Abs. [22] [23] [24] Covalent modification of one of the many surface lysine residues present in Abs has the potential to affect antigen-recognition properties, either directly (through modification of residues in the complementarity determining region (CDR)) or indirectly through allosteric effects. Trastuzumab contains between 80-95 lysine residues which potentially can act as a chemical handle for direct attachment to FNB-NIREPs. Thus, the conjugation of trastuzumab with FNB-terminated tri(ethylene glycol) monomethyl ether (FNB-TEG) as a PEO-diblock copolymer model was explored. Trastuzumab was incubated with FNB-TEG at various molar ratios (40:1, 20:1, and 10:1 FNB-TEG to antibody) in sodium borate buffer, and the resulting Ab-TEG conjugates were analyzed using a statistical MALDI-MS method as reported previously (Figure 3 ). Briefly, by acquu·ing a mass spectmm of each Ab-TEG preparation in replicates greater than 3, it is possible to detect a minimal mass difference of 119 Da between IgG and its conesponding conjugates to a 95% confidence level, even in linear detection mode. 25 The average number of moles of the conjugate attached per mole of IgG can be subsequently calculated from the difference in the observed masses of Ab-TEG conjugates and the unconjugated t.rastzumab blank (0: 1 preparation), divided by the molecular weight of the FNB-TEG conjugate. The results, sulllll1arized in Table 1 , showed that we are able to reproducibly vaty the degree of trastuzumab modification from 1 FNB-TEG group (10:1 preparation) to ~4-5 FNB-TEG groups ( 40: 1 preparation). 
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Spector Group (June 2014-June 2015):
The antigen-recognition propetties of the trastuzumab conjugates were assessed il1 an inummofluorescent assay usil1g a htm1ru1 breast cancer cell line MCF10A following il1duction of HER2 expression using a doxycycline regulated promoter. The lentiviral doxycycline-inducible system was originally used to express shorthailpin RNA for gene expression suppression 26 but has been modified by the Spector group for MCFlOA Her2
DAPI
Traz
Uncoupled FNB-TEG coupled protein expression in doxycycline-regulated HER2 expression in MCF10A cells. HER2 expression was induced by addition of doxycycline (+); cel ls were fixed and permeabilized and HER2 expression determined by incubation with narve (uncoupled) and FNB-TEG-coupled trastuzumab, and visualized by FITCconjugated anti-human lgG and cell nuclei by DAPI DNA staining.
regulated expression of cloned cDNAs. The results showed that showed covalently modified trastuzumab retail1ed antigen recognition properties ( Figure 4 ). The antigen-bil1ding activity was fi.ut her quantified by MCF10A HER2+ extract nitrocellulose slot blot using a fluorescently labeled secondruy anti-ln1111an IgG ( Figure 5 ); tras tuzt1111ab coupled to an average of 2 TEG groups retail1ed -65% of its antigen reactivity, which was compru·able to the blank sample incubated with conjugation buffer tmder the reaction conditions (~70%). These results showed that the reduction in ru1tigen binding affmity is associated with handling the antibody (e .g. temperature, buffer, pm'ification steps) rather than through modification of the CDR region. The conclusions from these expet'iments show that we ru·e able to control the munber of modi cations made on the surface of trastuzumab, and covalent attachment of a TEG chain does not occur in the antigen binding region. It is our expectation that we will be able to couple many copies of trastuzumab onto the surface of polymersomes. This, coupled with the demonstrated ability of surface-conjugated bioligands such as antibodies to cluster on fluid membrane polymersomes to maximise antigen binding affinity (ref) means that the multi-ligand effect of Ab-conjugated polymersomes should more than compensate for a ~30% drop in antigen binding affinity.
Synthesis of FNB
OB18 ( Trastuzumab (Genentech) was desalted into 1X sodium borate buffer (285 mOsm, pH 8.50) using a Amicon Ultra 0.5 mL 100 kDa MWCO Centrifugal Filter using the manufacturer's instructions. The desalted antibody was diluted to a 4 mg/mL concentration with buffer, and the concentration checked by UV-vis absorption at 280 nm (vide supra). FNB-TEG, dissolved in buffer, was added to the desalted antibody at molar ratios of 40:1, 20:1, or 10:1. The reactions were shaken at 750 rpm at 37 °C for 20 h, and then desalted into 1X PBS (285 mOsm, pH 7.40) for immunofluorescence studies, or MilliQ water for MALDI analysis. NMR: 
Modification of antibodies with FNB-TEG
MALDI-MS analysis of trastuzumab-TEG conjugates
MALDI-MS spectra were recorded on an AB Sciex 4800 Plus MALDI-ToF instrument in linear detection mode using a sinapinic acid matrix. For each sample, 3 separate mass spectra were obtained, and the peak maxima were averaged, and subtracted from that obtained from unmodified trastuzumab. The mass differences were divided by the molecular weight of the FNB-TEG conjugate to obtain the average degree of substitution per antibody.
Immunofluorescence
Cells were plated in complete media on 15 mm round uncoated glass coverslips. Cells were fixed in 3.7% formaldehyde/1X phosphate buffered saline (PBS), and permeabilized by incubation with a solution of 1% NP-40 detergent/PBS. For staining of cellular expressed HER2, cells were incubated with 400 ng/mL rabbit anti-HER2 antibody (Santa Cruz SC-284) / 100 µg/mL bovine serum albumin/ 0.02% azide/PBS. Protein was visualized with AlexaFluor 488 goat anti-rabbit secondary antibody and imaged on Leica fluorescence.
Slot blot
Spector Group: A protein solution of either HER2+/-cellular extracts or trastuzumab antibody was diluted in PBS and 200-400 µL was added to a slot blot manifold applied under vacuum onto pre-wetted Protran nitrocellulose membranes. Membranes were dried and then incubated with a 5% non-fat dry milk (5% Blotto) in PBS for 1 h at room temperature to block unoccupied binding sites then incubated with either anti-human IgG-800 near-IR antibody (Molecular Probes/Live Technologies) or trastuzumab followed by anti-human IgG-800 in 1% Blotto. Following incubation with antibody solutions, non-specifically bound antibodies were removed by 3 × 15 minute washes with PBS containing 0.05% Tween 20. The level of secondary antibody was determined by scanning on a LI-COR Odyssey near-IR blot scanner.
NIREP construction
Using our newly validated functionalized OB18 polymer, we can construct NIREPs using our wellestablished methodology (Figure 7 ). NIREP synthesis was carried out using the thin-film hydration method as previously described. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] An organic solution of FNB-functionalized PEO(3600)-b-PBD(6800) diblock copolymer (FNB-OB18), shortchain PEO(1300)-b-PBD(2500) (OB2) and PZn N NIRF at a 5:95:5 molar ratio was spotted onto a roughened Teflon plate and allowed to evaporate to form a uniformly coated surface. After residual solvent removal under high vacuum for >24h, 1X PBS buffer (285 mOsm, pH 7.40) is added and the films incubated at 60 °C for 24 h, followed by 90 minutes of sonication in a bath sonicator. Nanoscale, unilamellar NIREPs are subsequently obtained using procedures analogous to those used to formulate liposomes (sonication, freeze-thaw and extrusion). Ten freeze-thaw cycles are carried out by alternatively placing the samples in liquid N 2 , followed by a 5 minute sonication in a water bath at 60 °C. Extrusion through 400 nm polycarbonate membranes is carried out at 60°C using a thermobarrel extruder under moderate pressures. NIREP vesicle size and morphology is characterized by cryogenic transmission electron microscopy (cryo-TEM) and dynamic light scattering (DLS). Having validated that the variation in batches of Ab-NIREPs is not due to inadvertent deactivation of trastuzumab through covalent modification or conjugation conditions, we sought to quantify the degree of non-specific absorption of trastuzumab to the polymersome surface ( Figure 8 ). To assess this, we incubated trastuzumab with unfunctionalized 5:95 OB18/OB2 polymersomes, under identical coupling and purification conditions to which we will carry out the Ab conjugation to FNBfunctionalized NIREPs. Previously, we used the enhanced BCA assay to determine the protein content of our polymersome samples, which has a sensitivity range of 5-250 µg/mL protein. However, on reexploring our protocols, we have determined that at a polymersome concentration of 5 mg/mL, the lower detection limit of 5 µg/mL protein corresponds to approximately 19 antibodies/polymersome; we thus conclude that this assay is too insensitive for our needs. Unfortunately, we found that the micro-BCA assay, with an ideal detection range of 0.5-200 µg/mL protein (corresponding to a lower detection range of 2 Abs/NIREP), is incompatible with polymersomes resulting in false positives ( Figure 9 ). The Spector Group developed a sensitive methodology for the detection of antibody concentration by Westem blot analysis; Figure 10 shows a })roof-of-principle experiment analyzing 1mfunctionalized NIREPs incubated with (Samples A-B; 1:1 molar ratio trastuzmnab/OB18) and without (Samples C-D) t:rastuzumab. The fluorescently labeled antihuman seconda1y IgG antibody shows linear sensitivity over a wide range of trastuzumab concentrations and is capable of detecting as little as 0.1 ng A b.
Assessment of non-specific absorption
Coupling strategy to assess degree of non-specific absorption
Unftmctionalized 5:95 OB18/0B2 NIREPs were desalted into L"X sodium borate buffer (pH 8.50, 285 mOsm), and concentrated to -5 mg/mL concentration by centrifugal filtration (Amicon Ultra 4 mL 100 kDa MWCO centrifugal filter). The polymersome concentration was determined by UV -vis absorption of the sample conected for scattering, using previously determined e}.iinction coefficients. 32 Similarly, trastuzumab (Genentech) was desalted into IX sodium borate, and concentrated to a ~ 10 mg/mL concentration by centrifugal ftltration; concentration was determined by absorption at 280 nm. Desalted trasn1zumab and NIREP were combined at fixed molar ratios (e.g. 40:1 molar ratio of OB18 to trastuzumab) and agitated at 750 rpm for 24 h at 37 °C. The reaction mixture was ptui.fied on a Sephacryl S-500 column with IX PBS (1 mL/min, detection at 280. 426 and 700 run). Purified NIREP fractions were combined and concentrated to -5 mg/mL concentration by centrifugal filtration.
Assessing protein content of NIREPs
The amount of trastuzumab bouncllcoupled to a NIREP was detemlined by Western blotting. Samples, and a dilution series of known quantities of pure trastuzmnab antibody were denatured with laemlli denaturing buffer, sized on denatme PAGE geL and transfen·ed to nitrocellulose using an iBlott transfer apparatus (Life Technology). TI1e membrane was blocked with 5% Blotto for 1 hat room temperature then incubated with anti-human IgG-800 antibody in 1% Blotto. Non-specifically bound antibodies were removed by 3 x 15 minute washes with PBS containing 0.05% Tween 20 and the le. vel of trastuzmnab signal was determined by scanning on a LI-COR Odyssey near-IR blot scanner. A calibration plot of the diluted trastuzumab was determined and the amount oftmshlZlunab in each NIREP preparation was calculated.
Final NIREP concentration, detennined by UV-vis as described above, was convetted into average nmnber of particles per unit volmne, N, using the following equation: 37 (1)
Where W is the polymer mass (in mg/mL), Do is the average outer diameter of the polymersome (obtained by DLS). D; is the diameter of the polymersome lun1en (calculated Do-2/, where 1 is the polymersome membrane thickness, detetmined by c1yo-TEM), 38 and pis the density of OB2 (previously determined as 1.08 g/cm 3 ). 39 The concentration of trastuzumab in the sample, Y, determined by Western blot analysis, is converted to number of antibodies, M:
Where mw is the molecular weight of trastuzumab (145,531 g/mol) and N A is Avogadro's constant. The number of antibodies per polymersome is thus calculated M/N. Samples were measured in triplicate.
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What opportunities for training and professional development has the project provided? Training
Melanie O'Sullivan (Postdoctoral Research Associate)
Training in colloidal synthesis and characterization including cryogenic transmission electron microscopy; biological techniques; imaging, in vitro biology.
Professional development
Melanie O'Sullivan (Postdoctoral Research Associate)
Attendance at conferences and seminars listed under major activities. In addition, attended a grant writing workshop "Writing a Convincing Research Plan" at Duke University. Grant writing experience. Dr. O'Sullivan has had the opportunity to acquire very broad interdisciplinary training (e.g., nanoscale science, cancer biology, in vitro and in vivo imaging, cellular biology). She has learned new science and developed important new technologies, built networks of collaborators and contacts, learnt important skills for working in interdisciplinary environments, and is thus better equipped for a future career and leadership role in science, technology, and medicine.
How were the results disseminated to communities of interest?
One manuscript detailing new fluorophores relevant to NIREP fabrication was published (Design of Diethynyl Porphyrin Derivatives with High NIR Fluorescence Quantum Yields, K. Susumu and M. J. Therien, J. Porphyrins Phthalocyanines 2015, 19, 205-218. DOI: 10.1142/S1088424614501107).
What do you plan to do during the next reporting period to accomplish the goals?
Our next step is to apply the methodology described in Section 3.2 using FNB-functionalized NIREPs to generate anti-HER2-NIREPs. The degree of covalently coupled antibodies will be determined by subtracting the number of non-specifically absorbed antibodies, determined from the experiments previously described. With anti-HER2 NIREPs in hand, we will determine uptake into HER2-and HER2+ MCF10A cells (expression of HER2 regulated by dox, see Figure 4 ), by analyzing fluorescence intensity per cell by ImageStream flow cytometry.
We will then use our established roadmap for the fabrication of antibody-conjugated NIREPs to generate annexin-V NIREPs for the analysis of apoptosis in parental and lapatinib-resistant breast cancer cell lines when treated with lapatinib. Furthermore, we will profile the phenotypic changes associated with lapatinib resistance by fabricating CD146-and E-cadherin-targeted NIREPs.
IMPACT
What was the impact on the development of the principal discipline(s) of the project?
Breast cancer is not a single disease: it can be categorized into a series of subtypes dependent on which faulty protein or proteins in the cell are responsible for uncontrolled growth of the tumor. For example, tumors that overproduce the HER2 protein are called HER2+ tumors; this subtype of breast cancer is associated with a higher likelihood of the disease spreading, thus a lower life expectancy. Over the past 15 years, significant advancements in the treatment of breast cancer have been made by recognition that not all breast cancers are the same. Drugs such as trastuzumab or lapatinib have been designed to inhibit a specific faulty protein; this selectivity reduces the number of harmful side effects, while halting growth of the tumor. Despite these advances, in 2010, there were approximately 438,000 deaths worldwide due to breast cancer, the vast majority of these as a result of the cancer spreading. One major issue is that the primary tumor in the breast may differ in subtype to other tumors found elsewhere in the body. In addition, tumor cells that initially respond to treatment can evolve to become resistant to the effects of the drug, leading to disease recurrence, and this remains a significant problem in the treatment of breast cancer. The mechanisms by which the cells become resistant to these drugs are numerous and not fully understood; the situation is further complicated by the fact that tumors found elsewhere in the body may evolve in different ways in response to treatment. This complexity makes the design of new therapy regimens that circumvent drug resistance currently difficult. The inability to biopsy every tumor at regular time intervals in a patient with advanced breast cancer remains a significant impediment towards delivering an effective personalized approach to the treatment of advanced stage breast cancer. This research will develop the first non-invasive imaging method that allows tumors to be characterized into subtypes, without the need for a biopsy. Our system uses non-toxic, biodegradable nanoparticles (called "NIREPs"), which when injected, selectively recognize proteins on the surface of cells that mark the cell as cancerous, and transmit information about the cell using non-harmful frequencies of light that can be detected from outside of the body. We will develop NIREPs that can distinguish between different breast cancer subtypes, including which cancers are likely to respond to or be resistant to therapy. The non-invasive nature of this technology will allow us to study the evolution of therapy resistance over time: by understanding how tumors respond to therapy, more effective treatment regimens can be developed that will delay or halt the development of drug resistance, drastically improving patient survival and remission rates. Importantly, we expect this platform to exhibit sufficient sensitivity to detect microscopic sites of metastatic disease that are currently undetectable by conventional patient imaging methods such as MRI or PET. Approximately 20-30% of women with early stage breast cancer have such tumors in their bone marrow; such patients have poorer prognosis for survival. Early detection of these sites and prompt intervention through an informed treatment program would drastically improve patient survival and remission rates.
We expect that once our methodology for the synthesis of antibody-conjugated NIREPs is established, it will provide a roadmap for future research in this area.
What was the impact on other disciplines?
Nothing to report.
What was the impact on technology transfer?
What was the impact on society beyond science and technology?
Dr. O'Sullivan, a young Ph.D. scientist, has been exposed to research challenges, experimental methods, research investigators, collaborators, and a research environment that will strongly influence her future career directions in the field of breast cancer research.
CHANGES/PROBLEMS
Changes in approach and reasons for change
Actual or anticipated problems or delays and actions or plans to resolve them
Changes that had a significant impact on expenditures
Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents
Significant changes in use or care of human subjects
Significant changes in use or care of vertebrate animals.
Significant changes in use of biohazards and/or select agents
Nothing to report. 
PRODUCTS
Publications, conference papers, and presentations
6)
"Nanoscale Agents for Optical Imaging", given at the Department of Chemistry, University of Kentucky, Lexington, Kentucky, January 23 rd , 2015.
7)
"Antibody-Targeted Near-IR Emissive Polymersomes for the Non-Invasive Molecular Profiling of Tumors", given at Cancer Nanotechnology: Nanomedicines from Laboratory to Clinical Reality, West Dover, Vermont, June 29 th , 2015.
Website(s) or other Internet site(s)
Technologies or techniques
Inventions, patent applications, and/or licenses
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What individuals have worked on the project?
Name:
Michael J. Therien 
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SPECIAL REPORTING REQUIREMENTS
COLLABORATIVE AWARDS: The Partnering PI, Dr. Neil Spector will submit his report.
APPENDICES
INTRODUCTION
The design and synthesis of near infrared (NIR) absorption materials that possess large absorptive oscillator strengths and high fluorescence quantum yields are important to molecular imaging [1] [2] [3] [4] [5] and solar energy conversion technologies [6] [7] [8] [9] [10] . Likewise, the efficient utilization of NIR sunlight is a key feature of natural photosynthesis, which exploits NIR-absorbing dyes such as chlorophylls and pheophytins [11] . Relative to the tremendous attention that has been paid to the design and synthesis of low band gap chromophores and materials [12] [13] [14] [15] [16] [17] [18] [19] , much Jess focus has been given to the development of strategies that channel enhanced oscillator strength into the low energy optical transitions of such compositions. For example, only a limited number of conjugated organic structures possess both high oscillator strength NIR (S 0~S 1 ) absorptions and corresponding high (S 1~S0 ) fluorescence quantum yields [20, 21] . In general, a higher S 0~S 1 absorptive extinction coefficient should correlate with a larger S 1~S0 radiative rate constant, congruent with the Strickler-Berg relationship [22] ; most strongly absorbing organic NIR dyes, however, are not impressive emitters, due in many cases to large magnitude S 1 state non-radiative rate constants that are readily rationalized within the context of the energy gap law [23] .
Porphyrins are tetrapyrrole 1t-conjugated systems, and the lowest energy absorption bands of simple tetraphenylporphyrin or octaethylporphyrin monomers range typically over the 600 to 650 nm spectral regime and feature modest absorptive extinction coefficients (£ < 10 4 M-1 .cm-1 ). Modification of the porphyrin 1t-skeleton can further reduce the HOMO-LUMO gap; the electronic structures of such reduced band gap porphyrins can in general be rationalized using Gouterman's four orbital model [24] . In a simple (porphinato )metal complex having D 4 h symmetry, the LUMO is doubly degenerate, and the HOMO and HOMO-I are nearly degenerate in energy; as a result, substantial configuration interaction mixes the (a 1 .~e,) and (~~g) transitions. Constructive and destructive combinations of these one-electron transitions give rise to an intense shorter-wavelength Soret band and a weakly absorbing longer-wavelength Q-band. While removal of frontier orbital (HOMO/HOMO-I, LUMO/ LUMOt 1) degeneracy is expected to result in augmentation of the Q-band absorptive extinction coefficient, relatively few examples exist of low band gap porphyrin derivatives that possess intense NIR Q-bands [25] [26] [27] [28] [29] .
In contrast, the chlorophylls, natural porphyrin derivatives, possess lowest energy Q-bands with significant extinction coefficients(£: 0.5 -1 x 1()5 M· 1 .cm· 1 ) [30, 31] ; some chlorophyll derivatives and related macrocycles feature substantial fluorescence quantum yields that range from -0.05 to 0.3 [32, 33] . While significant strides have been made in recent years regarding chlorophyll synthesis [33] [34] [35] , the more involved nature of their fabrication limits many possible applications of these structures. Chromophores within the phthalocyanine family also exhibit intense low energy electronic absorption bands (£: 1 -2 x 10 5 M· 1 .cm-1 ); while a few examples of these chromophores are known that feature both substantial NIR absorptivity and significant fluorescence quantum yield (0.1 -0.8) [36, 37] , it is important to point out that extensive modulation of phthalocyanine absorptive properties and photophysics is limited by the modest frontier orbital electron density localized at the periphery of the macrocycl~fused benzene rings [38] .
We have explored synthesis and electronic properties of meso-ethynyl porphyrin derivatives for nonlinear optics [60, [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] , optoelectronic devices [82] [83] [84] [85] [86] [87] , and fluorescence-based optical imaging technologies [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] .
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Ethyne groups fused to the porphyrin meso-positions provide significant electronic interaction with the macro cycle ~-derived HOMO and remove the degeneracy of the low-lying empty eg orbitals [39, 42, 45, 50, 55] . Here we report the synthesis and optical properties of conjugated 5,15-diethynyl(porphinato)zinc(ll) complexes that feature conjugated terminal groups having varying degrees of proquinoidal character (Fig. 1 ) that drive intense Q-band absorptions; the uncommon emissive properties of these new fluorophores based on a (5,15-diethynylporphinato) zinc(ll) framework are discussed within the context of the Strickler-Berg relationship.
EXPERIMENTAL
Materials
All manipulations were carried out under nitrogen previously passed through an 0 2 scrubbing tower (Schweitzerhall R3-ll catalyst) and a drying tower 2) were synthesized as described previously [50, 54, 66] . A number of key precursors were synthesized as reported earlier [99] . All NMR solvents, and all other chemicals, were used as received.
Chemical shifts for 1 H NMR spectra are relative to the tetramethylsilane (TMS) signal in deuterated solvent (TMS, o = 0.00 ppm). All J values are reported in Hertz.
Flash and size exclusion column chromatography were performed on the bench top, using respectively silica gel (EM Science, 230-400 mesh) and Bio-Rad Rio-Beads SX-1 as media. CI mass spectra were acquired at the Mass Spectrometry Center at the University of Pennsylvania. MALDI-TOF mass spectroscopic data were obtained with a Voyager-DE RP instrument (PerSeptive Biosystems): samples for these experiments were prepared as micromolar solutions in either CH 2 Cl 2 or THF, a nd ditbrano] (Sigma-Aldrich) was utilized as the matrix.
Instrumentation 1 H NMR spectra were recorded on either 250 MHz AC-250, 300 MHz DMX-300, or 500 MHz AMX-500 Brtiker spectrometers. Electronic absorption spectra were recorded on a Shimadzu PharmaSpec UV1700 spectrophotometer. Fluorescence spectm were obtained with a Spex Fluorolog-3 spectrophotometer (Jobin Yvon Inc. , Edison, NJ) that utilized aT-channel configuration with red sensitive R2658 Harnamatsu PMT and liquid nitrogen cooled InGaAs detectors. The obtained fluorescence spectra were corrected using the spectral output of a calibrated light source supplied by the National Bureau of Standards. Fluorescence quantum yields were measured on N 2 -purged solutions at room temperature. Tetraphenylporphyrin in benzene (<1> 1 = O.l3) was used as a standard [100] . The fluorescence quantum yields of each sample were calculated using the following equation (Equation l ) <l> M F. . A,. . n; <l> f(r) = .F; . A, . n: ( 1) where <1> 1 is the fluorescence quantum yield, F is the area under the corrected fluorescence band (expressed 1.14 x 1 o· 5 mol), Cui(l.Omg, 5.3 x J0· 6 mol) and dryTHF (7.0 mL) were added to a 100-mL round-bottom flask. Ar was bubbled into the reaction mixture for 5 min before piperidine (0.50 mL) was added. The reaction mixture was stirred at 45 °C for 3.5 h under Ar. After the solvent was evaporated, the residue was chromatographed on silica gel with 8:1 hexanes:THF as the eluent. Yield 0.063 g (72% based on 50.4 mg of (5, 15-diethynyl-10,20bis [2' ,6' -bis(3" ,3" -dimethyl-1 "-butyl oxy)phenyl] porphinato)zinc(II)). 1 4-r~-Dodecy loxyphenyl-4' ,4' ,5' ,5' -tetramethyl-1' ,3' ,2' -dioxa borolane. 4-n-Dodecy Ioxyiodobenzene (99) (1.00 g, 2.58 X 10· 3 mol), dichloro(1,1'-bis(diphenylph osphin o) ferrocene] pall a diu m(II) · di chi orom ethane adduct (0.106 g, 1.30 x 10 4 mol) were added to 1,2dichloroethane(5.0mL)andEt3N(l.OmL, 7.2x 10· 3 mol). 4,4,5,5-Tetramethyl-1,3,2-dioxaborolane (0.56 mL, 3.9 x 1 o-3 mol) was added, and the reaction mixture was stirred at 75 °C for 1.5 h under Ar. After cooling, the solvent was evaporated. The residue was chromatographed on silica gel with 2: 1 hexanes:CHCI 3 as the eluent. Yield 0.674 g (67% based on 1.00 g of 4 -n-dodecyloxyiodobenzene). [1, 2, 5] thiadiazole. N,N-Dihexylamino-4-vinylbenzene [99] (0.154g, 5.36x 10 4 mol),4,7-diiodobenzo[c] [1, 2, 5] thiadiazole [99] (0.309 g, 7.96 x 10 4 mol), Pdzdba3 (50.4 mg, 5.5 X 10" 5 mol), and dry 1,4-dioxane (7.0 mL) were added to a 100-mL round-bottom flask. Ar was bubbled into the reaction mixture for 5 min before dicyclohexylmethylamine (0.50 mL) and P(t-Buh (10 wt% in hexanes, 1.00 mL, 3.3 x 10 4 mol) were added. The reaction mixture was stirred at 57 °C for 48 h under Ar. After the solvent was evaporated, the reaction mixture was chromatographed on silica gel with 8:1 hexanes:THF. The product was further purified by size exclusion column chromatography (BioRad Bio-Beads SX-1 packed in THF, gravity flow). Yield 42.2 mg (14% based on 0.154 g of N ,N-dihexylamino-4-vinylbenzene). 
RESULTS AND DISCUSSION
Synthesis Chromophores 2-9 are based on a (5,15-diethynylporphinato)zinc(ll) framework and feature symmetric donor or acceptor units appended at the meso-ethynyl positions that derive from phenylene and benzo[c] [1, 2, 5] thiadiazole building blocks; these structures, along with the TMS-protected (5,15-diethynyl-10,20bis[3' ,5' -bis(9" -methoxy-1 ",4", 7" -trioxanonyl)phenyl] porphinato)zinc(ll) reference monomer (1) , are shown in Fig. 1 . Scheme 1 details the syntheses of fluorophores 3-9. The proquinoidal spacer unit, benzo[ c ] [ 1 ,2,5] thiadiazole, which extends 1t-conjugation from the porphyrin core for 4-9, has been used not only as a common building block to enhance electronic delocalization within 1t-conjugated oligomers and polymers, but also as an electron accepting moiety [55, 99, 101, 102] .Incorporationofbenzo[c][l,2,5] thiadiazole into conjugated organic networks is made Copyright C 2015 World Scient~ic Publishing Company facile through the agency of palladium-catalyzed crosscoupling reactions. In 2-9, each aromatic unit is linked by either ethyne or ethene units through Sonogashira or Heck coupling reactions. The 10-and 20-meso-positions of the (porphinato)zinc cores of 1-9 feature either 3,5-bis(9' -methoxy-1 ',4',7' -trioxanonyl)phenyl (1) or 2,6-bis(3',3' -dimethyl-1 '-butyloxy)phenyl substituents (2) (3) (4) (5) (6) (7) (8) (9) to ensure high solubility. Fluorophores 2-9 were synthesized by Pd-mediated cross-coupling reactions involving appropriately modified terminal substituents and 5,15-dibromo-or 5,15-diethynyl(porphinato)zinc(ll) synthons (Experimental Section).
Steady-state electronic absorption spectra
Electronic absorption spectra of NIR fluorophores 2-9 recorded in THF solvent are displayed in Fig. 2 . These chromophores feature lowest energy Q absorption bands that are significantly red-shifted (1985-3070 cm· 1 ) and intensified (-20 to 50-fold enhanced in oscillator strength) relative to the analogous transition manifold of [5,10,15,20-tetraphenyl(porphinato) ]zinc(ll) (TPPZn) [100] . While chromophores 2 and 3 manifest spectral signatures akin to other closely related, [5,15-bis[(aryl) ethynyl] -1 0,20-diphenylporphinato ]zinc(II) complexes [42] , note that structures 4-9, which incorporate benzo[c] [1, 2, 5] Table 1 ). As conjugation is expanded at the porphyrin (5, 15-bis(benzo[ c] [ 1 ',2' ,5']thiadiazol-4'ylethynyl) moieties [4~5~ (6, 7, 8, 9) ] (Fig. 2, Table 1 ), increasingly pronounced B-state (Soret) transition manifold splitting is evident; note that the Q.(O,O) transition extinction coefficients for fluorophores 6-9 surpass those of their most intense respective B-band absorption, and exceed 10 5 M· 1 .cm· 1 , a value comparable to Q-state absorptions characteristic of chlorophylls and phthalocyanines [30, 37] . In contrast to the full widths at half maximum (FWHM) values for the B-band manifolds of 6-9, which span 4430-6480 cm· 1 note the x-polarized Q-state absorption maximum for 8 is 928 cm· 1 red-shifted relative to that for 3. The enhanced 1t-conjugation afforded by the benzo[c][l, 2, 5] thiadiazolyl group is consistent with its proquinoidal character [104] , and earlier work which establishes that meso (benzo[ c] [ 1 ,2,5] thiadiazol-4-ylethynyl) substituents Fluorescence s pectra Figure 2 also h.iglilights the ·fluorescence spectra recorded for chromophores 2-9 in THF solvent; these spectra mirror the respective lowest energy Q-state absorption manifolds for these chromopbores. The fluorescence energy maxima red-shift with increasing Copyright e 2015 World Scientaic Publishing Company degrees of conjugation [4-?5-? (6, 7, 8, 9) ] (Fig. 2 . Thble 1); note in this regard that f.luoropbore 7 features an emission band maximum centered at 748 run, and that structures .2-9 feature narrow fluorescence bands (620 cm· 1 < FWHM(S 1 -?S 0 ) < 1130 em·') !hat are significantly reduced with respect to the S 1 -?S 0 FWHM value determined for TPPZn (1924 em·'). Note also that the narrow fluorescence bands of 2-9 resemble the spectral breadths of their respective lowest energy Q-state absorption manifolds ( Table 1) and feature low-magnitude Stokes shifts (155-620 em·'), congruent with a minimal degree of excited-state structural relaxation relative the ground-state conformation for these chromophores.
Strickler-Berg analysis of the S 1 -state photo physics of ftuorophores 2-9
Relative to the (porphinato)zinc chromophore TPPZn (<1> 1 = 0.033), the fluorescence quantum yields Table 2 ). Further, given the shape and intensity of the steady-state fluorescence spectra of these monomeric (porphinato)zinc chromophores that bear either 5,15-bis[(aryl)ethynyl] or 5,15-bis(benzo[c] [1 ',2',5']thiadiazol-4'-ylethynyl) substituents, coupled with the fact that the emission band maxima of these species are significantly red-shifted (1690-3160 em·') with respect to the TPPZn benchmark (Table 1) , suggest an analysis of the S 1 state photophysics within the context of the Strickler-Berg model, which relates increases in the integrated oscillator strength of the lowest-energy ground-state absorption band with a con·espond.ing augmentation of the radiative decay rate constant (k,, Equation 2) [22] . k, = 2.880x 10· 9 ,l (vJ)~. :: J &llnv (2) Here k, is radiative decay rate constant. 11 is the refractive index oft be solvent, g 1 andg, are the respective degeneracies of the ground and excited states. f. is the molar extinction coefficient v is the frequency of the transition in em·•. The te1m (v/),4:, is expressed as;
( 3) where I is the intensity of the fluorescence spectrum, measured in terms of relative numbers of quanta at each frequency. The fluorescence quantum yield (<1> 1 ) is simply described by Equation 4;
where k., describes the magnitude of the non-radiative decay rate constant. which corresponds to the sum of the intemal conversion (k,,) and intersystem crossing (k 1 "') rate constants. Provided that the magnitudes of the nonradiative rate remain approximately constant within a famiJy of closely related cbromophores, an increase in the integrated oscillator strength results in a corresponding increase in the fluorescence quantum yield . Figure 3 highlights the x-polarized Q-state oscillator strength dependent fluorescence quantum yields, radiative ·--·-·-·• ·-·--5-·-·-··-· ··-1--··-·..1.·-·-··-·-·---· ·-· -·-··-··-·-·-··-·-·--· x-Polarized Q-state oscillator strength (a) rate constants. and non-radiative. rate constants of fluoropbores 1-9 relative to the TPPZn benchmark. Note tbe distinct increase in the magnitude of the radiative mte constant with increasing x-polarized Q-state oscilJator strength (Fig. 3B) , and that the measured k, values for tluorophores 5-9 exceed that of the TPPZn by more than an order of magnitude. This apparent Striclcer-Berg dependence of the radiative rate constant upon the integrated lowest energy S 0 4S 1 oscillator strength gives rise to a family of porphyrin-based NIR fluorophores in which the longest wavelength emitter (7 , 748 om) features a fluorescence quantum yield (<1> 1 = 0.35: Tables 1 and 2 ) that exceeds tbat of chromopbores 1-6 and 9, wbich emit to tbe blue of this wavelength.
As emission wavelengths approach the NIR spectral domain, the simple Stricker-Berg predicted dependence of tbe radiative rate constant upon the magnitude of the integrated oscillator strength is generally mitigated by expected energy gap law effects [23] , where increasing magnitudes of the S 0 -S 1 internal conversion rate constant (k;c) track with diminishing S 0 --S 1 energy gaps and thus sharply decrease <l>.f In these ch.romophores, two factors conspire to enhance c;l) 1 as emission wavelength increases over tbe 650--750 om spectral domain. The first of these derives from the fact that the proquinoidal benzo[c] [1 ,2,5] tbiadiazole unit minim.izes the extent of excitedstate structural relaxation relative the ground-state conformation [55] for cbromophores 4-9, reflected by the narrow fluorescence bands and modest Stokes shifts determined for these species (Fig. 2 ; Tables 1 and 2) , and thereby reduces S 1 -S 0 Franck--Condon overlap important for determining the magnitude of k 1 c. The second factor that drives this unusual dependence of <1> 1 upon emission wavelength stems from the fact that for these ethyneelaborated (porphinato)zinc derivatives, intersystem crossing into the triplet manifold generates T 1 states that manifest more spatially confined excitations relative to the globally delocalized sl states of these chromophores [41, 45, 47, 54, 62] . This diminished overlap of S 1 and T 1 state wavefunctions mitigates S 1 -T 1 intersystem crossing rate constants (k~.w: values), and thus serves to counter-balance the effect of augmented Franck -Condon mediated internal conversion that typically accompanies S 0 -S 1 energy gap reductions; this effect has been detailed previously for closely related compounds [57] . Thus, for 4-9, extension of x-polarized conjugation of the (5,15-diethynylporphinato)zinc(II) framework via the benzo[c] [1, 2, 5] thiadiazole moiety causes the magnitude of k, to increase faster than does the magnitude of k., as emission wavelength increases, providing substantial fluorescence quantum yields that manifest a weak energy gap law [23] dependence over this spectral regime.
CONCLUSION
We describe a design strategy for (porphinato)zincbased chromophores that possess large NIR fluorescence quantum yields. These fluorophores are based on a (5,15diethynylporphinato)zinc(Il) framework and feature symmetric donor or acceptor units appended at the rneso-ethynyl positions via benzo[ c] [ 1 ,2,5] thiadiazole moieties. These chromophores possess red-shifted absorption and emission bands relative to TPPZn and (5,15-diethynyl-10,20-arylporphinato)zinc(ll) benchmarks that range between 650 and 750 nm and bear distinct spectral similarities to those manifest by chlorophylls and structurally related molecules.
Interestingly, the measured radiative decay rate constants for these emitters track with the integrated oscillator strengths of their respective x-polarized Q-band absorptions, and thus define an unusual family of high quantum yield NIR fluorophores in which emission intensity is governed by a simple Strickler-Berg dependence. These photophysical properties derive from the facts that: (i) the proquinoidal benzo[c] [1, 2, 5] thiadiazole unit minimizes the extent of excitedstate structural relaxation relative the ground-state conformation [55] , and (ii) meso-ethynyl elaborated (porphinato)zinc compounds are characterized by T 1 states that are more spatially confined than their globally delocalized S 1 states [41, 45, 47, 54, 62] , which result in diminished S 1 -T 1 intersystem crossing rate constants relative to conventional (porphinato)zinc chromophores. For these NIR fluorophores, these effects cause the magnitude of k, to increase faster than does the magnitude of k., as emission wavelength increases, providing substantial fluorescence quantum yields that manifest a weak energy gap law [23] dependence over the spectral regime (685-750 nm) spanned by these emitters. These designs that take advantage of these photophysical properties make possible broadly absorptive and strongly Copyright C 2015 World Scient~ic Publishing Company emissive NIR fluorophores that derive from a monomeric (5, 15-diethynyl-porphinato )zinc framework.
Brief description of project's goals: The goal of this project is to create a highly sensitive non-invasive imaging modality to characte1ize the molecular profile of all breast cancer sites of disease, including micrometastases. Specific Aims:
1. Profile a panel of molecularly heterogeneous human breast cancer cell lines using cocktails of antibodyconjugated NIREPs; 2. To phenotype p1imruy and metastatic sites of breast cancer using targeting NIR-emissive polymersomes and dete1mine their response to targeted therapies. ffhis is t.he current roject. Brief description of project' s goals and specific aims: The goal of this project is to exploit de novo protein design to understand the essential design plinciples of photosynthetic energy transduction and storage. An integrated, multi-disciplinary approach is employed towru·d this goal, and focuses on the evolution of peptidecofactor complexes that undergo photoinduced charge-transfer reactions, where the protein matrix stabilizes the chru·ge-separated state and guides the efficient sepru·ation of electrons and holes. There is no overlap with the current project.
his is a new active project. Brief description of project' s goals and specific aims: This project focuses on ftn1her development of the NS-FOD (nano-scintillator fiber optic dosimeter), a device based on nanoscale scintillating materials that provides accurate, pinpoint, and real-time radiation dosimetly for clinical brachytherapy (implanted radiation), extemal berun radiation, elecn·on therapy, IMRT (intensity modulated radiation therapy), and VMAT (volumetlic modulated ru·c therapy) applications.
There is no overlap with the current project. his is a new active project.
